Re­gen­eron stum­bles in PhI Lib­tayo com­bo study as safe­ty con­cerns force sus­pen­sion

Faced with un­ex­pect­ed safe­ty con­cerns, Re­gen­eron has slammed the brakes on a Phase I study test­ing a com­bi­na­tion of its PD-1 drug Lib­tayo and an ear­ly-stage an­ti­body.

The com­pa­ny dis­closed on clin­i­cal­tri­ that the sus­pen­sion is due to a se­vere ad­verse event, but didn’t go any fur­ther. En­roll­ment will be halt­ed and while the pa­tients cur­rent­ly in the tri­al won’t re­ceive ad­di­tion­al treat­ment, they will still be mon­i­tored for safe­ty. End­points News has reached out to the com­pa­ny for more de­tails

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.